VEGF 165 Protein

Produktnummer ABIN7275824

Produktdetails

Target: VEGF 165

Protein-Typ: Recombinant

Spezies: Human

Quelle: HEK-293 Cells

Sequenz: Ala27-Arg191

Reinheit: > 95% as determined by Tris-Bis PAGE,> 95% as determined by HPLC

Sterilität: 0.22 μm filtered

Endotoxin-Niveau: Less than 1EU per μg by the LAL method.

Biological Activity Comment: Immobilized Human VEGF165 at 1μg/ml (100μl/well) on the plate. Dose response curve for Human VEGFR2, mFc Tag with the EC50 of 74.2ng/ml determined by ELISA. See testing image for detail.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/mL is recommended (usually we use 1 mg/mL solution for lyophilization). Dissolve the lyophilized protein in distilled water.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 5 % trehalose is added as protectant before lyophilization.

Lagerung: 4 °C,-80 °C

Informationen zur Lagerung: Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Antigendetails

Target: VEGF 165

Andere Bezeichnung: VEGF165

Hintergrund: VEGF, VEGFA, MVCD1, VAS, VEGFMGC70609, VPF, RP1-261G23.1, MGC70609,Human papillomavirus (HPV) infection is an established risk factor for cervical carcinogenesis. VEGF165 was significantly higher, whereas VEGFC and VEGFD were significantly lower in malignant cervical carcinoma tissues as compared to normal cervix tissues. Expression levels of VEGF121 and VEGFC were significantly associated with type of tumor growth while VEGF165 was significantly associated with lymph node metastasis.

Molekulargewicht: 19.2 kDa. Due to glycosylation, the protein migrates to 20-30 kDa based on Tris-Bis PAGE result.